Mabs

杂志介绍

Mabs杂志介绍

《Mabs》是一本以English为主的未开放获取国际优秀期刊，中文名称单克隆抗体，本刊主要出版、报道医学-MEDICINE, RESEARCH & EXPERIMENTAL领域的研究动态以及在该领域取得的各方面的经验和科研成果，介绍该领域有关本专业的最新进展，探讨行业发展的思路和方法，以促进学术信息交流，提高行业发展。该刊已被国际权威数据库SCIE收录，为该领域相关学科的发展起到了良好的推动作用，也得到了本专业人员的广泛认可。该刊最新影响因子为5.6，最新CiteScore 指数为10.7。

本刊近期中国学者发表的论文主要有：

• Cadonilimab, a tetravalent PD-1/CTLA-4 bispecific antibody with trans-binding and enhanced target binding avidity

  Author: Pang, Xinghua; Huang, Zhaoliang; Zhong, Tingting; Zhang, Peng; Wang, Zhongmin Maxwell; Xia, Michelle; Li, Baiyong

• High-throughput optofluidic screening of single B cells identifies novel cross-reactive antibodies as inhibitors of uPAR with antibody-dependent effector functions

  Author: Lourenco, Andre Luiz; Chuo, Shih-Wei; Bohn, Markus F.; Hann, Byron; Khan, Shireen; Yevalekar, Neha; Patel, Nitin; Yang, Teddy; Xu, Lina; Lv, Dandan; Drakas, Robert; Lively, Sarah; Craik, Charles S.

• Characterization of the high-affinity anti-CTLA-4 monoclonal antibody JS007 for immune checkpoint therapy of cancer

  Author: Guan, Jiawei; Liu, Hongchuan; Chai, Yan; Yu, Jie; Yao, Jian; Wang, Jing; Pan, Zhiwei; Zhang, Jing; Zhou, Yuehua; Liu, Hui; Yao, Sheng; Qi, Jianxun; Feng, Hui; Gao, George. F. F.; Wang, Qihui; Shi, Yi; Tan, Shuguang

• Antibody-drug conjugates with HER2-targeting antibodies from synthetic antibody libraries are highly potent against HER2-positive human gastric tumor in xenograft models.

  Author: Kuo WY¹, Hsu HJ¹, Wu CY², Chen HS¹, Chou YC¹, Tsou YL¹, Peng HP¹, Jian JW^1,3,4, Yu CM¹, Chiu YK¹, Chen IC¹, Tung CP¹, Hsiao M¹, Lin CL¹, Wang YA⁵, Wang AH⁶, Yang AS¹.

英文介绍

Mabs杂志英文介绍

mAbs is a multi-disciplinary journal dedicated to the art and science of antibody research and development. The journal has a strong scientific and medical focus, but also strives to serve a broader readership. The articles are thus of interest to scientists, clinical researchers, and physicians, as well as the wider mAb community, including our readers involved in technology transfer, legal issues, investment, strategic planning and the regulation of therapeutics.